Skip to main content

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
03/06/2025
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
03/06/2025
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
02/25/2025
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology
News
12/04/2024
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy study, the FDA has approved zenocutuzumab for adult patients with advanced, unresectable, or metastatic NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma who have progressed on or...
Based on results from the eNRGy...
12/04/2024
Oncology

News

News
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
03/06/2025
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
03/06/2025
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
02/25/2025
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology

Interactive Features

Quiz
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology